{"organizations": [], "uuid": "39849d474a11be7fe6e8ca7e453879566c365d97", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-uniqure-q1-revenue-35-mln-vs-i-b-e/brief-uniqure-q1-revenue-3-5-mln-vs-i-b-e-s-view-2-8-mln-idUSASC09Y6T", "country": "US", "domain_rank": 408, "title": "Uniqure Q1 Revenue $3.5 Mln Vs I/B/E/S View $2.8 Mln", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-30T19:55:00.000+03:00", "replies_count": 0, "uuid": "39849d474a11be7fe6e8ca7e453879566c365d97"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-uniqure-q1-revenue-35-mln-vs-i-b-e/brief-uniqure-q1-revenue-3-5-mln-vs-i-b-e-s-view-2-8-mln-idUSASC09Y6T", "ord_in_thread": 0, "title": "Uniqure Q1 Revenue $3.5 Mln Vs I/B/E/S View $2.8 Mln", "locations": [], "entities": {"persons": [], "locations": [{"name": "huntington", "sentiment": "none"}], "organizations": [{"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30, 2018 / 11:55 AM / Updated 21 minutes ago BRIEF-Uniqure Q1 Revenue $3.5 Mln Vs I/B/E/S View $2.8 Mln Reuters Staff\nApril 30 (Reuters) - Uniqure NV:\n* UNIQURE ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS COMPANY PROGRESS * Q1 REVENUE $3.5 MILLION VERSUS I/B/E/S VIEW $2.8 MILLION\n* Q1 EARNINGS PER SHARE VIEW $-0.74 — THOMSON REUTERS I/B/E/S\n* IND FILING FOR AMT-130 IN HUNTINGTON’S DISEASE EXPECTED IN SECOND HALF OF 2018\n* PATIENT ENROLLMENT EXPECTED TO BEGIN AHEAD OF SCHEDULE IN DOSE-CONFIRMATION STUDY FOR AMT-061\n* AMT-061 PIVOTAL STUDY ON TRACK TO COMMENCE IN Q3 OF 2018\n* CURRENTLY EXPECTS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS INTO EARLY 2020 Source text for Eikon: Further company coverage:", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-30T19:55:00.000+03:00", "crawled": "2018-04-30T15:09:52.003+03:00", "highlightTitle": ""}